Collaboration aims to harness Tevogen’s proprietary immunotherapy platform and Dr. Neal Flomenberg’s expertise in research and the transplantation of T cells
Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100-percent protection against SARS-CoV-2 infection following a single vaccination
Company announces publication of DARE-BV1 proof-of-concept study for proprietary thermosetting hydrogel formulation of clindamycin phosphate for one-time vaginal administration
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.